Talc Pleurodesis Through Very-Small-Bore Catheters in Patients with Recurrent Malignant Pleural Effusion

Ali Özgen

Department of Radiology, Yeditepe University School of Medicine, İstanbul, Turkey

Abstract

Objective: Malignant pleural effusion (MPE) is a frequent and disturbing complication of metastatic disease. Talc pleurodesis via percutaneously placed 12–18F catheters is an effective procedure to treat recurrent MPE. We aimed to determine the efficiency of talc pleurodesis through very-small-bore catheters in the treatment of recurrent malignant pleural effusion.

Methods: We performed 13 talc pleurodesis procedures in 10 patients with recurrent MPE via pre-existing 7F (6 patients) and 8F (4 patients) pig-tail catheters. We analyzed technical and clinical success of the procedure.

Results: All procedures were performed successfully. Complete or partial clinical success was achieved in 8 out of 10 patients. No major complication was observed.

Conclusion: Talc pleurodesis through 7F or 8F catheters may be performed in selected patients with reduced patient discomfort, and similar success rates that was obtained using higher caliber catheters in the treatment of recurrent MPE.

Keywords: Fluoroscopy, malignant, pleural effusion, pleurodesis, talc, therapy

INTRODUCTION

Malignant pleural effusion (MPE) is a frequent and disturbing complication of metastatic disease (1, 2). Talc pleurodesis is an effective procedure to treat recurrent MPE (3-7). Intrapleural administration of talc can be performed via videotoracoscopic or a chest tube, and this requires hospital admission (6, 7). Talc pleurodesis can also be performed as an outpatient procedure via percutaneously placed 12–18F catheters (4, 5, 8). The objective of this study was to present results of 13 talc pleurodesis procedures performed in 10 patients using 7F or 8F catheters, which, to the best of our knowledge, has not been presented in the literature before.

METHODS

Subjects

This study was approved by the Ethics Committee of our institution. Between September 2011 and December 2014, we performed 13 talc pleurodesis procedures in 10 patients with metastatic disease via pre-existing 7F (6 patients) and 8F (4 patients) pig-tail catheters. All patients were referred from the department of oncology with the diagnosis of recurrent MPE. One patient had metastatic mesothelioma, 4 had lung cancer, and 5 had metastatic breast cancer. All patients suffered from moderate to severe dyspnea before the procedure. Four patients were treated as outpatients, while 6 patients had been hospitalized during the procedure because of the systemic treatment they had received. The expected survival time was more than 3 months for all patients.
Pleural Catheter Placement
All patients were examined with ultrasound prior to pleural catheter placement. If the pleural fluid was anechoic or hypoechoic and has no septations, we aspirated a small amount using a 22G needle to see whether the fluid was hemorrhagic and/or dense. When we could easily aspirate a non-hemorrhagic fluid without any apparent septations and echoes on ultrasound, we inserted a 7F or 8F pig-tail catheter. Otherwise, we used a 12F or 14F pig-tail catheter with larger holes to treat such complicated pleural effusions. Patients with complicated pleural effusions were not considered as candidates for talc pleurodesis. All procedures were performed with real-time ultrasound guidance under local anesthesia with patients in a sitting position by an interventional radiologist. Informed consent was obtained from all patients.

Talc Pleurodesis
All procedures were performed via pre-existing catheters when the daily drainage of pleural fluid was less than 100 mL. The patient was instructed to lie in a supine position on the fluoroscopy table. The location of the catheter was checked under fluoroscopy by opening the stopcock and observing free pleural fluid drainage (Figure 1a). If free fluid drainage was not observed, 10–20 mL of iodinated contrast medium was given under fluoroscopic guidance to confirm the location of the catheter (Figure 1b). Then, 10 mL of 2% lidocain was given via the catheter into the pleural space. Patients were instructed to lie in supine and prone positions each for 10 min for lidocain to disperse evenly. Then, 4 g of sterile talc (Steritalc, Novatech, France) with an average particle size of 25 μm in 50 mL of 0.9% NaCl solution was given via the catheter. Intravenous analgesia was given by an anesthesiologist only when necessary. Stopcock was then closed after flushing the catheter with 5 mL of 0.9% NaCl solution. A control standard chest X-ray was obtained (Figure 1c). Patients were then instructed to lie supine, on the right side, prone, and on the left side each for 15 minutes for a total of 2 hours. Then, the stopcock was opened for free fluid drainage. Catheters were flushed with 10 mL of sterile saline twice daily. Once the drainage stopped, the catheter was removed.

Follow-up and Assessment of Efficacy
Patients were followed by the departments of oncology, chest diseases, and radiology with standard chest X-rays to determine the effectiveness of the pleurodesis, while they were routinely followed clinically. The efficacy of talc pleurodesis was defined in 3 categories during the follow-up: complete (none or minimal pleural fluid accumulation), partial (relapse of some fluid that did not require treatment), and failure (relapse of fluid that required further intervention). If pleurodesis failed, the procedure was repeated one more time with the same technique.

RESULTS
All procedures were performed easily as a single-step insertion. Three patients mentioned mild discomfort during the insertion, while the rest did not complain. We did not experience any difficulty in draining the fluid after pleurodesis. Although all patients suffered mild to moderate pain and experienced fever after the procedure, which required medication, no early or late serious complication was observed because of pleurodesis in any patient.

The patient with malignant mesothelioma died because of sepsis due to neutropenia after 2 months. During that period, no pleural fluid aspiration was required, although minimal effusion was noted in chest X-ray. The first patient with lung cancer responded completely, and only minimal pleural effusion was noted in the 12-month follow-up. The second patient with lung cancer died 5 months after pleurodesis because of cerebral metastasis. Although some pleural effusion recurred after 3 months, no drainage was indicated. The third patient with lung cancer required another session of pleurodesis after 3 weeks, which also failed in a month. This patient underwent video-assisted thoracoscopic surgery. The fourth patient with lung cancer required another session of talc pleurodesis after 3 months. No pleural intervention was required in this patient at 8-month follow-up, while minimal effusion was noted in chest X-rays. One patient with breast cancer responded completely, and no pleural effusion was noted in the 12-month follow-up. The second patient with breast cancer had minimal pleural effusion and/or thickening for the following 9 months. The third patient with breast cancer had some pleural effusion, which did not need any intervention for the following 9 months. The fourth patient with breast cancer died because of sepsis at the third month, with some recurrent effusion, which did not need any intervention. The fifth patient with breast cancer came...
back with moderate pleural effusion and mild shortness of breath in the 10th week. When pleural fluid was recurred after 2 aspirations with a 2-week interval, talc pleurodesis was repeated. The patient came back with shortness of breath and moderate pleural effusion after 1 month, which required fluid aspiration.

We had 4 complete and 3 partial clinical success cases out of 10 patients in the first round of pleurodesis and achieved a 70% success rate. We had also 1 complete success case out of 3 patients in the second round of pleurodesis and achieved an 80% total success rate, including complete and partial ones. With regard to interventions, we had 8 successful outcomes, 5 complete and 3 partial, out of 13 patients with pleurodesis (62%). Patient data and outcomes of the procedures are summarized at Table 1. Out of 8 patients with complete or partial successful pleurodesis, 7 mentioned moderate to high relief in dyspnea, while 1 patient mentioned minimal relief.

**DISCUSSION**

Malignant pleural effusion is a common complication of advanced malignancy (1, 2). The most common causes for MPE are lung cancer, breast cancer, lymphoma, ovarian cancer, and gastric cancer (1). Malignant mesothelioma, a very rare disease, may also present with large pleural effusion at the time of diagnosis (1). Dyspnea, cough, and chest pain are the primary symptoms of MPE (2). Even in patients respond to systemic treatment, local therapy for recurrent MPE may still be required (2).

Pleurodesis is defined as the insertion of a sclerosing agent into the pleural cavity to induce inflammation with the resulting adhesion of pleural layers. Although tetracycline, bleomycin, and iodopovidone have been used in pleurodesis in different success and complication rates, talc pleurodesis is a widely accepted and effective procedure to treat MPE (2–10). Sterile talc with an average particle size of 25 μm can be safely used in pleurodesis (11). Intrapleural administration of talc can be performed via videothoracoscopy or a chest tube, and this requires hospital admission (6, 7). However, pleurodesis via a percutaneously inserted 12–18F pig-tail catheter could be performed with hospital admission (4, 5).

Possible adverse events commonly observed in patients with talc pleurodesis include the incidence of fever and pain (2). All of our patients suffered mild to moderate pain and experienced fever after the procedure, which was easily controlled with medication. Although talc pleurodesis has been considered a somewhat safe intervention, complications such as acute pneumonitis, empyema, wound infection, and even acute respiratory failure may be observed in the follow-up of pleurodesis (2). We did not observe any early or late serious complications.

In this study, we present 13 talc pleurodesis procedures successfully performed via 7F or 8F catheters in 10 patients with recurrent MPE. These very-small-bore catheters never need dilation of the tract and are easily inserted as a single-step procedure. Width of the holes of the catheter was wide enough to inject the talc slurry effectively and to drain the fluid after the procedure. The 8F catheters were proven to be safe and effective in the treatment of pleural effusion, but to the best of our knowledge, they have not been used in talc pleurodesis previously (12).

The major limitation of this study is the limited number of patients. Our total complete and partial clinical success rates, 8 out of 10 patients (80%) and 8 out of 13 interventions (62%), respectively, were similar to those reported previously, although we had a limited number of patients and the time of follow-up differed significantly (2, 3).

**CONCLUSION**

In conclusion, talc pleurodesis through 7F or 8F catheters may be performed in selected patients in the treatment of recurrent MPE. In comparison with 12–18F catheters, 7F or 8F catheters may be favored because of reduced discomfort and ease of insertion with similar efficacy. Further comparative studies, possibly with more subjects, are required to reveal the exact efficacy of this method.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years), sex</th>
<th>Primary disease</th>
<th>Follow up</th>
<th>Result</th>
<th>Follow up</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>49, male</td>
<td>Malignant mesothelioma</td>
<td>2 months</td>
<td>Complete</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>56, male</td>
<td>Lung cancer, adenocarcinoma</td>
<td>12 months</td>
<td>Complete</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>71, male</td>
<td>Lung cancer, adenocarcinoma</td>
<td>5 months</td>
<td>Partial</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>67, male</td>
<td>Lung cancer, small cell</td>
<td>3 weeks</td>
<td>Failure</td>
<td>1 month</td>
<td>Failure</td>
<td></td>
</tr>
<tr>
<td>65, male</td>
<td>Lung cancer, adenocarcinoma</td>
<td>3 months</td>
<td>Failure</td>
<td>8 months</td>
<td>Complete</td>
<td></td>
</tr>
<tr>
<td>64, female</td>
<td>Breast cancer, invasive ductal</td>
<td>12 months</td>
<td>Complete</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>56, female</td>
<td>Breast cancer, invasive lobular</td>
<td>9 months</td>
<td>Complete</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>68, female</td>
<td>Breast cancer, invasive ductal</td>
<td>9 months</td>
<td>Partial</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>44, female</td>
<td>Breast cancer, invasive ductal</td>
<td>3 months</td>
<td>Partial</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>48, female</td>
<td>Breast cancer, invasive ductal</td>
<td>10 weeks</td>
<td>Failure</td>
<td>1 month</td>
<td>Failure</td>
<td></td>
</tr>
</tbody>
</table>

**Table 1. Patient data and outcome of the pleurodesis procedures**

- **Ethics Committee Approval:** Ethics committee approval was received for this study from the ethics committee of Yeditepe University.
- **Informed Consent:** Written informed consent was obtained from patients who participated in this study.
- **Peer-review:** Externally peer-reviewed.
- **Conflict of Interest:** No conflict of interest was declared by the author.
- **Financial Disclosure:** The author declared that this study has received no financial support.
REFERENCES